Contrasting Taro Pharmaceutical Industries (TARO) and The Competition
Taro Pharmaceutical Industries (NYSE: TARO) is one of 116 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Taro Pharmaceutical Industries to related companies based on the strength of its profitability, risk, dividends, valuation, earnings, analyst recommendations and institutional ownership.
Volatility & Risk
Taro Pharmaceutical Industries has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, Taro Pharmaceutical Industries’ competitors have a beta of 0.90, meaning that their average stock price is 10% less volatile than the S&P 500.
This is a summary of recent ratings and price targets for Taro Pharmaceutical Industries and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Taro Pharmaceutical Industries||0||1||0||0||2.00|
|Taro Pharmaceutical Industries Competitors||827||3703||6739||182||2.55|
As a group, “Pharmaceuticals” companies have a potential upside of 23.37%. Given Taro Pharmaceutical Industries’ competitors stronger consensus rating and higher probable upside, analysts plainly believe Taro Pharmaceutical Industries has less favorable growth aspects than its competitors.
Institutional and Insider Ownership
14.2% of Taro Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 43.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 13.8% of Taro Pharmaceutical Industries shares are owned by company insiders. Comparatively, 11.8% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Taro Pharmaceutical Industries and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Taro Pharmaceutical Industries||$806.92 million||$465.05 million||11.03|
|Taro Pharmaceutical Industries Competitors||$8.20 billion||$2.68 billion||-1.31|
Taro Pharmaceutical Industries’ competitors have higher revenue and earnings than Taro Pharmaceutical Industries. Taro Pharmaceutical Industries is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
This table compares Taro Pharmaceutical Industries and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Taro Pharmaceutical Industries||49.69%||19.71%||17.74%|
|Taro Pharmaceutical Industries Competitors||-2,845.49%||-66.88%||-8.71%|
Taro Pharmaceutical Industries competitors beat Taro Pharmaceutical Industries on 8 of the 13 factors compared.
About Taro Pharmaceutical Industries
Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical products in over 25 countries. The Company’s owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The Company’s other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.
Receive News & Ratings for Taro Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.